CYP2

Cytochrome P450 CYP2 comprises a major branch of the human cytochrome P450 superfamily and catalyzes Phase I oxidative metabolism of endogenous compounds and xenobiotics, thereby contributing substantially to drug clearance and chemical detoxification processes^[1][2]. Mechanistically, CYP2 enzymes function as heme-dependent monooxygenases that convert lipophilic substrates into more hydrophilic metabolites, a key biochemical step that facilitates downstream elimination pathways and influences pharmacokinetic behavior^[1]. Within drug-metabolizing pathways, CYP2 subfamily members, including CYP2C9, CYP2C19, and CYP2D6, participate in the metabolism of a large proportion of clinically used therapeutics and are major determinants of interindividual variability in drug response^[1][2][3]. In disease-relevant and translational research models, genetic variation in CYP2 genes is closely associated with altered metabolic phenotypes, affecting drug efficacy, toxicity, and susceptibility to clinically significant drug-drug interactions^[3][4]. Compared with related cytochrome P450 isoforms, CYP2 enzymes are distinguished by extensive genetic polymorphism and substrate selectivity, features that make them central targets in pharmacogenomics and precision medicine investigations^[3][4]. For experimental applications, selective inhibitors and substrates are widely used to define CYP2-mediated metabolic pathways, characterize enzyme activity, and evaluate metabolism-dependent pharmacological or toxicological outcomes during drug discovery and development^[1][4].